Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IP6K1 | Q92551 | 17/20 | 0.64 |
| ▸ | IP6K3 | Q96PC2 | 17/20 | 0.64 |
| ▸ | IP6K2 | Q9UHH9 | 17/20 | 0.64 |
| ▸ | MEN1 | O00255 | 2/20 | 0.64 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.64 |
| ▸ | NPC1 | O15118 | 1/20 | 0.64 |
| ▸ | POLB | P06746 | 1/20 | 0.64 |
| ▸ | RAB9A | P51151 | 1/20 | 0.64 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.60 |
| ▸ | TP53 | P04637 | 1/20 | 0.60 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.60 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.50 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.50 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6260259 | 0.86 | IP6K1 (0.52) | IP6K1IP6K3IP6K2MEN1KMT2A | |
| SCHEMBL25990396 | 0.79 | IP6K1 (1.00) | IP6K1IP6K3IP6K2MEN1KMT2A | |
| SCHEMBL10396398 | 0.76 | IP6K1 (1.00) | IP6K1IP6K3IP6K2MEN1KMT2A | |
| SCHEMBL25352847 | 0.75 | IP6K1 (1.00) | IP6K1IP6K3IP6K2MEN1KMT2A | |
| SCHEMBL31265140 | 0.75 | IP6K1 (1.00) | IP6K1IP6K3IP6K2MEN1KMT2A | |
| SCHEMBL25989723 | 0.73 | IP6K1 (1.00) | IP6K1IP6K3IP6K2MEN1KMT2A | |
| SCHEMBL5917986 | 0.72 | MAPK14 (0.50) | IP6K1IP6K3IP6K2MEN1KMT2A | |
| SCHEMBL25991315 | 0.72 | IP6K1 (0.74) | IP6K1IP6K3IP6K2MEN1KMT2A | |
| SCHEMBL25990975 | 0.71 | IP6K1 (1.00) | IP6K1IP6K3IP6K2MEN1KMT2A | |
| SCHEMBL25992046 | 0.71 | IP6K1 (1.00) | IP6K1IP6K3IP6K2MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023200441-A1 | ANTIVIRAL HETEROCYCLIC COMPOUNDS | ENANTA PHARMACEUTICALS, INC. (US) | 2023-10-19 | — | — | WO | disclosed |
| US-20230108803-A1 | ANTIVIRAL HETEROCYCLIC COMPOUNDS | ENANTA PHARMACEUTICALS, INC. | 2023-04-06 | — | — | US | disclosed |
| EP-1934174-A1 | AZETIDINES AS MEK INHIBITORS FOR THE TREATMENT OF PROLIFERATIVE DISEASES | Exelixis, Inc. (US) | 2008-06-25 | — | — | EP | disclosed |
| WO-2007044515-A1 | AZETIDINES AS MEK INHIBITORS FOR THE TREATMENT OF PROLIFERATIVE DISEASES | EXELIXIS, INC. (US) | 2007-04-19 | — | — | WO | disclosed |
| EP-1587511-A2 | TREATMENT OF DISEASES WITH ALPHA-7 NACH RECEPTOR FULL AGONISTS | Pharmacia & Upjohn Company LLC (US) | 2005-10-26 | — | — | EP | disclosed |
| EP-1572205-A2 | TREATMENT OF DISEASES WITH COMBINATIONS OF ALPHA 7 NICOTINIC ACETYLCHOLINE RECEPTOR AGONISTS AND OTHER COMPOUNDS | Pharmacia & Upjohn Company LLC (US) | 2005-09-14 | — | — | EP | disclosed |
| EP-1572300-A1 | COMBINATION FOR THE TREATMENT OF ADHD | Pharmacia & Upjohn Company LLC (US) | 2005-09-14 | — | — | EP | disclosed |
| WO-2004064836-A2 | TREATMENT OF DISEASES WITH ALPHA-7 NACH RECEPTOR FULL AGONISTS | PHARMACIA & UPJOHN COMPANY LLC (US) | 2004-08-05 | — | — | WO | disclosed |
| WO-2004052461-A1 | COMBINATION FOR THE TREATMENT OF ADHD | PHARMACIA & UPJOHN COMPANY LLC (US) | 2004-06-24 | — | — | WO | disclosed |
| WO-2004052348-A2 | TREATMENT OF DISEASES WITH COMBINATIONS OF ALPHA 7 NICOTINIC ACETYLCHOLINE RECEPTOR AGONISTS AND OTHER COMPOUNDS | PHARMACIA & UPJOHN COMPANY LLC (US) | 2004-06-24 | — | — | WO | disclosed |
| WO-2004039366-A1 | NICOTINIC ACETYLCHOLINE AGONISTS IN THE TREATMENT OF GLAUCOMA AND RETINAL NEUROPATHY | PHARMACIA & UPJOHN COMPANY LLC (US) | 2004-05-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230108803-A1 | ANTIVIRAL HETEROCYCLIC COMPOUNDS | ACE, HPRT1, ACE2 | IP6K1 2026/4885IP6K3 1670/4885IP6K2 2781/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.